Fundraise / allotmentMajor development· Adverse for the businessFiled on BSE ·

Neogen Chemicals approves Q1 FY27 unaudited results and in-principle ₹600 crore raise

Neogen Chemicals · Chemicals & Petrochemicals

Arthneeti Research DeskPublished 1 min read
₹600 CrFundraise / allotment

Key highlights

  • Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2026 on July 24, 2026; Chandabhoy & Jassoobhoy issued limited review reports
  • In-principle approval to raise up to Rs. 600 crores via equity or other securities including QIP, subject to shareholder and regulatory approvals
  • Consolidated insurance claim receivable was Rs.200.85 crores as of June 30, 2026; Crisil downgraded the rating on July 17, 2026, raising NCD coupon from 10.50% to 11.00%

Why it's rated major development: credit rating downgrade is always high

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Board Meeting Outcome for Outcome Of Board Meeting Held On 24-07-2026

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Neogen Chemicals

Other fundraise / allotment filings this fortnight

All fundraise / allotment filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.